EXHIBIT 5.1
| | |
| | |
| |
| | Reference: 99472/5 |
February 26, 2024 | | |
| |
enGene Holdings Inc. 4868 Rue Levy, Suite 220 Saint-Laurent, QC H4R 2P1 | | |
RE: enGene Holdings Inc. - Registration Statement on Form S-1
Dear Sirs and Mesdames:
We have acted as Canadian counsel to enGene Holdings Inc., a corporation governed by the Business Corporations Act (British Columbia) (the “Corporation”), in connection with the transactions contemplated by a business combination agreement dated May 16, 2023 (the “Business Combination Agreement”) by and among Forbion European Acquisition Corp., (“FEAC”), Can Merger Sub, Cayman Merger Sub, and the Corporation. The Corporation is filing a registration statement on Form S-1 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”), relating to the registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”), for resale by the Selling Holders named in the Registration Statement (the “Selling Holders”) of up to (i) 6,462,016 common shares (“Common Shares”) in the capital of the Corporation (the “PIPE Shares”) and 2,783,949 warrants to purchase Common Shares (“Warrants”) issued in connection with the PIPE Financing and a Non-Redemption Agreement to certain Selling Holders; (ii) 14,295,943 Common Shares (the “Registration Rights Shares”) and 3,602,640 Warrants held by Selling Holders party to the Registration Rights Agreement; (iii) 6,386,589 Common Shares that may be obtained by the Selling Holders upon the exercise of the Warrants described in (i) and (ii) above (the “Selling Holders Warrant Shares”); and (iv) 20,000,000 Common Shares issued pursuant to the company’s private placement for gross proceeds of US$200,000,000, (the “Private Placement”) which closed on February 20, 2024 (the “Private Placement Shares” and, together with the PIPE Shares and the Registration Rights Shares, the “Registered Shares”). The Registration Statement also registers under the Securities Act the offer and sale by the Corporation of up to 9,794,498 Common Shares that may be obtained upon the exercise of outstanding Warrants (including Selling Holder Warrants that are publicly resold by the Selling Holders) (the “Corporation Warrant Shares” and together with the Selling Holders Warrant Shares, the “Registered Warrant Shares”).
The Warrants are governed by the warrant agreement dated as of December 9, 2021 (the “Warrant Agreement”) by and between FEAC and Continental Stock Transfer & Trust Company, as trustee (the “Trustee”), as the same was amended, assigned and assumed pursuant to the warrant assignment, assumption and amendment agreement (the “Warrant Amendment Agreement” and, together with the warrant agreement, the “Warrant Documents”) entered into by and among the Corporation and the Trustee on October 31, 2023.
Terms used in this opinion that are defined in the Business Combination Agreement, and are not otherwise defined herein, have the same meanings herein as in the Business Combination Agreement.